Abstract
Polygenic Scores (PGSs) offer the ability to predict genetic risk for complex disease across the life course; a key benefit over short-term prediction models. To produce risk estimates relevant for clinical and public health decision making, it is important to account for any varying effects due to common risk factors such as age and sex. Here, we develop a novel framework to estimate for cumulative incidences over the life course and produce country-, age-, and sex-specific estimates of cumulative incidence stratified by PGS for 18 high-burden diseases by integrating PGS associations from 7 studies in 4 countries (N=1,197,129) with disease incidences from the Global Burden of Disease. PGSs had a significant sex-specific effect for 5 diseases (asthma, hip osteoarthritis, gout, coronary heart disease, type 2 diabetes) with all but type 2 diabetes exhibiting a larger effect in men. PGS had a larger effect in younger individuals for 13 diseases, with the effects decreasing linearly with age. We showed for breast cancer that, relative to individuals in the bottom 20% of polygenic risk, the top 5% attain an absolute risk for screening eligibility 16.3 years earlier. For T2D, men and women in the top 1% reached the threshold aged 24.8 (95% CI: 22.5 – 27.6) and 22.3 (95% CI: 20.0 – 25.3) respectively. Individuals in the bottom 1% of PGS did not reach the risk threshold by age 80. Our easily extendable framework increases the generalizability of results from biobank studies and the accuracy of absolute risk estimates by appropriately accounting age and sex-specific PGS effects. Our results highlight the potential of PGS as a screening tool which may assist in the early prevention of common disease.
Competing Interest Statement
Kristi Läll has participated as an analyst in a collaboration research project at the Institute of Genomics, University of Tartu, which was funded by Geneto OÜ. No other authors have conflicts of interest to declare.
Funding Statement
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016775. N.M is the recipient of funding by the Academy of Finland (grant number 331671), University of Helsinki HiLIFE Fellows Grant and Finska Läkaresällskapet. K.L and R.M received funding from the Estonian Research Council grant PUT (PRG1911).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019. The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 10 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, BB2021_65, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/150/2022 Section 12, 13, 14, 15, 16, 17, 18, and 23, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and amendments BB_2021-0140, BB_2021-0156 (August 26 2021, Feb 2 2022), BB_2021-0169, BB_2021-0179, BB_2021-0161, AB20-5926 and amendment #1 (April 23 2020)and it's modification (Sep 22 2021), Biobank Borealis of Northern Finland_2017_1013, 2021_5010, 2021_5018, 2021_5015, 2021_5023, 2021_5017, 2022_6001, Biobank of Eastern Finland 1186/2018 and amendment 22 Section /2020, 53 Section /2021, 13 Section /2022, 14 Section /2022, 15 Section /2022, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Section 8/2021, Section 9/2022, Section 10/2022, Section 12/2022, Section 20/2022, Section 21/2022, Section 22/2022, Section 23/2022, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: ARC_2021_1001. Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382). UK Biobank data used in this study were obtained under approved application 78537. The genotyping in Tr øndelag Health Study and work presented in here was approved by the Regional Committee for Ethics in Medical Research, Central Norway (2014/144, 2018/1622, 2018/411492). All participants signed informed consent for participation and the use of data in research. Ethical approval for the GS:SFHS study was obtained from the Tayside Committee on Medical Research Ethics (on behalf of the National Health Service) The activities of the EstBB are regulated by the Human Genes Research Act, which was adopted in 2000 specifically for the operations of the EstBB. Individual level data analysis in the EstBB was carried out under ethical approval 1.1-12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), using data according to release application N05 from the Estonian Biobank. The informed consent process for the Genomics England 100,000 Genomes Project has been approved by the National Research Ethics Service Research Ethics Committee for East of England-Cambridge South Research Ethics Committee. The analysis using Mass General Brigham Biobank is approved under IRB protocol 2022P001736.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵+ These authors share senior authorship.
Data Availability
Individual level data in this study are not publicly available due to legal and privacy limitations, but they can be accessed through individual participating biobanks. The FinnGen data may be accessed through Finnish Biobanks' FinBB portal (www.finbb.fi; email: info.fingenious@finbb.fi). The Trøndelag Health Study data may be accessed by application to the HUNT Research Centre. Researchers interested in Estonian Biobank can request the access at https://www.geenivaramu.ee/en/access-biobank. De-identified data of the MGB Biobank that supports this study is available from the MGB Biobank portal. Restrictions apply to the availability of these data, which are available to MGB-affiliated researchers via a formal application. UK Biobank data are available through a procedure described at http://www.ukbiobank.ac.uk/using-the-resource/. Genomics England data is available through an application process described here: https://www.genomicsengland.co.uk/research/academic/join-gecip. Generation Scotland data may be accessed through an application process described here: https://www.ed.ac.uk/generation-scotland/for-researchers/access Summary level data are reported in tables and supplementary tables. The GWAS summary statistics used are publicly available and listed in Supplementary Table 4. The Global Burden of Disease data used here is available from http://ghdx.healthdata.org/.
